Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II).

doi:10.1006/gyno.1998.4972

Back to search

Article

Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II).

Gynecologic oncology - 1 Jul 1998

Husain A, Rosales N, Schwartz G K, Spriggs D R

Abstract excerpt

A novel approach to counteracting drug resistance is the development of nontoxic agents that are able to preferentially increase the sensitivity of tumor cells to the cytotoxicity of chemotherapy. The possibility that such an agent could be directed specifically against p53-defective tumor cells...

Topics

Adjuvants, Immunologic
Cisplatin
Dose-Response Relationship, Drug
Drug Resistance, Neoplasm
Female
Genes, p53
Humans
Mutation
Ovarian Neoplasms
Pentoxifylline
Tumor Cells, Cultured

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.